Lördag 5 April | 00:26:11 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-19 07:00 Kvartalsrapport 2025-Q3
2025-08-21 07:00 Kvartalsrapport 2025-Q2
2025-05-16 N/A X-dag ordinarie utdelning CANTA 0.00 SEK
2025-05-15 N/A Årsstämma
2025-05-13 07:00 Kvartalsrapport 2025-Q1
2025-02-21 - Bokslutskommuniké 2024
2024-12-02 - Extra Bolagsstämma 2025
2024-11-15 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning CANTA 0.00 SEK
2024-05-23 - Årsstämma
2024-05-21 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-22 - Kvartalsrapport 2023-Q2
2023-05-24 - X-dag ordinarie utdelning CANTA 0.00 SEK
2023-05-23 - Årsstämma
2023-05-23 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-30 - Kvartalsrapport 2022-Q2
2022-07-21 - Extra Bolagsstämma 2022
2022-05-24 - X-dag ordinarie utdelning CANTA 0.00 SEK
2022-05-23 - Årsstämma
2022-05-23 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning CANTA 0.00 SEK
2021-05-26 - Årsstämma
2021-05-26 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-10-13 - Extra Bolagsstämma 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning CANTA 0.00 SEK
2020-05-27 - Årsstämma
2020-05-27 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-28 - X-dag ordinarie utdelning CANTA 0.00 SEK
2019-05-27 - Årsstämma
2019-05-27 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-06-01 - X-dag ordinarie utdelning CANTA 0.00 SEK
2018-05-31 - Årsstämma
2018-05-15 - Kvartalsrapport 2018-Q1
2018-02-28 - Bokslutskommuniké 2017
2017-11-15 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-31 - X-dag ordinarie utdelning CANTA 0.00 SEK
2017-05-30 - Årsstämma
2017-05-15 - Kvartalsrapport 2017-Q1
2017-03-15 - Bokslutskommuniké 2016
2017-01-16 - Extra Bolagsstämma 2017
2016-11-21 - Kvartalsrapport 2016-Q3
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-25 - Årsstämma
2016-05-16 - Kvartalsrapport 2016-Q1
2016-03-02 - X-dag ordinarie utdelning CANTA 0.00 SEK
2016-03-01 - Bokslutskommuniké 2015
2015-11-17 - Kvartalsrapport 2015-Q3
2015-08-25 - Kvartalsrapport 2015-Q2
2015-05-19 - Kvartalsrapport 2015-Q1
2015-03-03 - Bokslutskommuniké 2014

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Cantargia är verksamt inom läkemedelsbranschen och fokuserar på utveckling av behandlingar för cancer och inflammatoriska sjukdomar. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Verksamheten är global med en huvudsaklig närvaro i Europa och Nordamerika. Cantargia grundades 2004 och har sitt huvudkontor i Lund, Sverige.
2025-03-25 21:30:00

Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced an upcoming presentation of preclinical data on the development of IL1RAP-targeting antibody-drug conjugates (ADCs). ADCs are already making a difference to cancer patients’ lives e.g. HER2-targeted ADCs in breast cancer, and the search for new targets is a high priority. Cantargia’s IL1RAP ADCs exploit IL1RAP expression by tumor cells and other cells in the tumor microenvironment (TME) to deliver toxic drugs into the tumor. The findings demonstrated safety, tolerability, and significant anti-tumor efficacy of IL1RAP targeting ADCs in preclinical animal models, suggesting promising therapeutic potential across a broad range of cancers expressing ILRAP.

The abstract is now published on the American Association for Cancer Research (AACR) website and the data will be presented at the AACR Annual Meeting April 25-30, 2025.

Cantargia’s IL1RAP platform technology can be used to generate new programs in addition to our nadunolimab and CAN10 clinical programs. These new data show how a novel anti-IL1RAP antibody can be combined with a cytotoxic payload to yield a highly potent and safe ADC.”, said David Liberg, Chief Scientific Officer of Cantargia. “We are looking forward to presenting these data on the upcoming AACR conference.

ADCs consist of a monoclonal antibody conjugated to a potent cytotoxic payload (drug) and thereby connects the selective targeting of antibodies with the cell killing abilities of chemotherapy. ADCs have brought substantial advancements in cancer therapy, offering significant benefits to patients. They are designed to target tumor cells with precision while minimizing damage to healthy cells. Many solid tumor types show increased expression of IL1RAP, both on tumor cells and on cells of the TME. Leveraging this tumor-specificity, IL1RAP-targeting ADCs, designed to selectively target IL1RAP-expressing cells, are being explored as a precision therapy for cancer.

In the presented work an antibody, screened and selected from Cantargia’s library of IL1RAP-binding antibodies, was conjugated to a tubulin-targeting cytotoxic payload. The conjugation to the payload did not compromise binding of the antibody to IL1RAP-expressing cells and the IL1RAP-targeting ADC showed IL1RAP-dependent tumor cell killing. The IL1RAP ADC was well tolerated and effectively suppressed tumor growth in all the animal models tested.

These preclinical results suggest that ADCs targeting IL1RAP may have promising therapeutic potential and Cantargia is looking forward to further optimizing and advancing the IL1RAP-targeting ADCs for use across a broad spectrum of cancers.

The studies involving anti-IL1RAP ADCs were performed in collaboration with ImmunoGen (now part of AbbVie), more details on the anti-IL1RAP ADC can be found in the abstract text.

The abstract title and texts will be posted onto the AACR online itinerary planner for the upcoming annual meeting in Chicago, IL on Apr 25-30, 2025., which can be found at https://www.aacr.org/meeting/aacr-annual-meeting-2025/meeting-resources/